IPI-493

Star0

DB13023InvestigationalSmall molecule

IPI-493 has been used in trials studying the treatment of Advanced Malignancies.

Formula / weight: C₂₈H₃₉N₃O₈ · 545.633 g/mol (avg)
Code names: NSC-255109

Resolves to

Compound

UNIISLQ1AJG3VBCAS64202-81-9ChEMBLCHEMBL339231PubChem9893658

Structure

InChIKeyXYFFWTYOFPSZRM-TWNAANEASA-NSMILESCO[C@H]1C[C@H](C)CC2=C(N)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O

Targets

P07900HSP90AA1

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with IPI-493, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account